Connect with us

National

AstraZeneca likely to run ‘additional’ COVID-19 vaccine trial as tricky questions emerge – SBS News

AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy US and EU regulatory approval.

Published

on

post featured image

AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine, its chief executive Pascal Soriot has reportedly said after questions over the results from its late-stage study.
Instead of adding the trial arm to an ongoing US process, a new study would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca’s studies, Soriot was quoted as saying in a Bloomberg News report.
“Now that we’ve found what looks like a better efficacy…

Click here to view the original article.